You have 9 free searches left this month | for more free features.

HLH

Showing 1 - 25 of 168

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

HLH Trial in Beijing (Teniposide)

Recruiting
  • HLH
  • Beijing, China
    Zhao Wang
Sep 15, 2023

HLH Trial in Beijing (Thiotepa)

Recruiting
  • HLH
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
May 10, 2023

Hemophagocytic Lymphohistiocytoses Trial in Cincinnati

Recruiting
  • Hemophagocytic Lymphohistiocytoses
    • Cincinnati, Ohio
      Cincinnati Children's Hospital Medical Center
    Oct 25, 2022

    Assessing the Presence of CT-DNA in Lymphoma Associated HLH

    Not yet recruiting
    • Lymphoma
    • Haemophagocytic Lymphohistiocytosis
      • (no location specified)
      Jan 25, 2023

      Hemophagocytic Syndrome Trial in Chongqing (cyclophosphamide, VP-16, Dexamethasone)

      Recruiting
      • Hemophagocytic Syndrome
      • Chongqing, China
        The Second affiliated Hosptial of Chongqing medical University
      Jun 28, 2023

      Hemophagocytic Lymphohistiocytoses, EBV, Metabonomics Trial in Beijing (observational)

      Not yet recruiting
      • Hemophagocytic Lymphohistiocytoses
      • +2 more
      • observational
      • Beijing, Beijing, China
        Beijing Friendship Hospital, Capital Medical University
      Dec 22, 2022

      Haemophagocytic Lymphohistiocytosis Trial (Ruxolitinib)

      Not yet recruiting
      • Haemophagocytic Lymphohistiocytosis
      • (no location specified)
      Feb 28, 2023

      Prospective Validation of the OHI Index

      Recruiting
      • HLH
      • +4 more
        • Kfar Saba, Israel
        • +1 more
        May 21, 2023

        HLH Trial in Beijing (Zanubrutinib)

        Recruiting
        • HLH
        • Beijing, China
          Beijing Friendship Hospital, Capital Medical University
        Apr 2, 2022

        Refractory, Recurrence, Hemophagocytic Lymphohistiocytosis Trial (GTP regimen)

        Not yet recruiting
        • Refractory
        • +2 more
        • GTP regimen
        • (no location specified)
        Sep 8, 2023

        PTLD, CAEBV, HLH Trial in Beijing (low-dose CD20 mAb injection)

        Enrolling by invitation
        • PTLD
        • +2 more
        • low-dose CD20 monoclonal antibody injection
        • Beijing, Beijing, China
          Beijing Friendship Hospital
        Feb 24, 2022

        Segmental Resection Combined With DEP Regimen for EBV-HLH

        Not yet recruiting
        • Hemophagocytic Lymphohistiocytosis
        • +2 more
        • Segmental bowel resection combined with the DEP regimen
        • Beijing, Beijing, China
          Zhao Wang
        Nov 9, 2023

        IFN? and Inflammatory Mediators in Hemophagocytic

        Completed
        • Hemophagocytic Lymphohistiocytoses
        • Blood Draws Data Collection
        • Boston, Massachusetts
          Brigham and Women's Hospital
        Sep 14, 2023

        Hemophagocytic Lymphohistiocytoses, Lymphoma Trial in Beijing (cytokine)

        Not yet recruiting
        • Hemophagocytic Lymphohistiocytoses
        • Lymphoma
        • cytokine
        • Beijing, Beijing, China
          Zhao Wang
        Oct 27, 2022

        Hemophagocytic Lymphohistiocytosis Trial in Beijing (L-DEP and PD-1 antibody)

        Not yet recruiting
        • Hemophagocytic Lymphohistiocytosis
        • L-DEP and PD-1 antibody
        • Beijing, China
          Beijing Friendship Hospital, Capital Medical University
        Apr 19, 2022

        Carbapenem Resistant Bacterial Infection, Hemophagocytic Lymphohistiocytoses Trial in Beijing (Carrimycin tablets)

        Not yet recruiting
        • Carbapenem Resistant Bacterial Infection
        • Hemophagocytic Lymphohistiocytoses
        • Carrimycin tablets
        • Beijing, Beijing, China
          Beijing Friendship Hospital, Capital Medical University
        Aug 4, 2023

        Hemophagocytic Lymphohistiocytosis Trial in Beijing (DEP combine with PD-1 antibody)

        Recruiting
        • Hemophagocytic Lymphohistiocytosis
        • DEP combine with PD-1 antibody
        • Beijing, China
          Beijing Friendship Hospital, Capital Medical University
        Feb 13, 2022

        Hemophagocytic Lymphohistiocytosis Trial in Beijing (Venetoclax, Dexamethasone, Etoposide)

        Recruiting
        • Hemophagocytic Lymphohistiocytosis
        • Beijing, Beijing, China
          Beijing Friendship Hospital, Capital Medical University
        Sep 15, 2022

        Immune Function and PD-1 Antibody Therapy Efficacy Predictors on

        Recruiting
        • Secondary Hemophagocytic Lymphohistiocytosis
        • Chronic Active Epstein-Barr Virus Infection
        • No intervention
        • Beijing, Beijing, China
          Beijing Friendship Hospital, Capital Medical University
        May 2, 2023

        PD-1 Antibody, Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus Trial in Beijing (L-DEP and PD-1 antibody)

        Not yet recruiting
        • PD-1 Antibody
        • +3 more
        • L-DEP and PD-1 antibody
        • Beijing, Beijing, China
          Beijing Friendship Hospital, Capital Medical University
        Mar 8, 2023

        Hemophagocytic Lymphohistiocytosis Trial in Philadelphia (tocilizumab)

        Withdrawn
        • Hemophagocytic Lymphohistiocytosis
        • Philadelphia, Pennsylvania
          Children's Hospital of Philadelphia
        Mar 11, 2022

        Adults Patients Having Non Severe HLH Trial in Bobigny (Itacitinib)

        Recruiting
        • Adults Patients Having Non Severe HLH
        • Bobigny, France
          Hôpital Avicenne
        Aug 22, 2022

        Secondary Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection Trial in Beijing (Rituximab

        Recruiting
        • Secondary Hemophagocytic Lymphohistiocytosis
        • Chronic Active Epstein-Barr Virus Infection
        • Rituximab Monotherapy
        • Beijing, China
          Zhao Wang
        May 18, 2022

        Safety and Efficacy Trial in Guangzhou (Sintilimab, Chidamide, Azacitidine)

        Not yet recruiting
        • Safety and Efficacy
        • Guangzhou, Guangdong, China
          Department of Medical Oncology,Sun Yat-sen University Cancer Cen
        Aug 16, 2021

        EBV Infection Trial in Suzhou (PD-1 mAb)

        Recruiting
        • EBV Infection
        • PD-1 monoclonal antibody
        • Suzhou, Jiangsu, China
          The First Affiliated Hospital of Soochow University
        Sep 1, 2021